Global Herpes Simplex Keratitis Treatment Market Size study, By Drug (Famciclovir, Valacyclovir, Acyclovir, Other Drugs), By Route of Administration (Topical, Injection, Oral), and Regional Forecasts 2022-2028

Global Herpes Simplex Keratitis Treatment Market Size study, By Drug (Famciclovir, Valacyclovir, Acyclovir, Other Drugs), By Route of Administration (Topical, Injection, Oral), and Regional Forecasts 2022-2028

Global Herpes Simplex Keratitis Treatment Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Herpes Simplex Keratitis disease can be defined as infection of the cornea. It is caused by recurrent infection of the cornea by herpes simplex virus (HSV). The virus is mostly transmitted by droplet transmission, and by direct inoculation. Herpes keratitis is one of the leading infectious causes of corneal ulcers and blindness worldwide. HSV infection usually heals without damaging the eye, but severe infections can lead to scarring of the cornea or blindness. The growing incidences of Herpes Simplex Keratitis and increasing research spending in pharmaceuticals sector as well as recent approvals from regulatory authorities are factors that are accelerating the global market demand. For instance, according to American Academy of ophthalmology (AAO)- as of 2020, the global prevalence of HSV keratitis was estimated 1.5 million yearly. Around 40,000 new cases result in severe visual impairment. In the United States, approximately 500,000 people diagnosed with ocular HSV. Furthermore, recent product approvals regulatory authorities would influence the growth of Herpes Simplex Keratitis Treatment Market. For instance, in September 2021, Hyderabad, India based Aurobindo Pharma received Indian patent for antiviral drug valacyclovir from the Indian Patent Office. This drug is sold in US and other countries under the trade name Valtrex. Also, growing healthcare infrastructure in emerging economies and increasing prevalence of infectious diseases are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost associated with Herpes Simplex Keratitis impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Herpes Simplex Keratitis Treatment market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing incidences of infections associated with the herpes simplex virus and presence of leading market players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing pharmaceuticals sector and recent approvals from regulatory authorities in the region, would create lucrative growth prospects for the Herpes Simplex Keratitis Treatment market across the Asia Pacific region.

Major market players included in this report are:
GlaxoSmithKline
Vectans Pharma
Blistex
Bausch Health
Aurobindo Pharma
Dr. Reddy's Laboratories
Cipla
Jubilant Cadista
Mylan
Emcure Pharmaceuticals Ltd

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug:
Famciclovir
Valacyclovir
Acyclovir
Other Drugs
By Route of Administration:
Topical
Injection
Oral
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Herpes Simplex Keratitis Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

GlaxoSmithKline
Vectans Pharma
Blistex
Bausch Health
Aurobindo Pharma
Dr. Reddy's Laboratories
Cipla
Jubilant Cadista
Mylan
Emcure Pharmaceuticals Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.